[go: up one dir, main page]

TN2009000380A1 - Novel human anti-r7v antibodies and uses thereof - Google Patents

Novel human anti-r7v antibodies and uses thereof

Info

Publication number
TN2009000380A1
TN2009000380A1 TNP2009000380A TN2009000380A TN2009000380A1 TN 2009000380 A1 TN2009000380 A1 TN 2009000380A1 TN P2009000380 A TNP2009000380 A TN P2009000380A TN 2009000380 A TN2009000380 A TN 2009000380A TN 2009000380 A1 TN2009000380 A1 TN 2009000380A1
Authority
TN
Tunisia
Prior art keywords
antibodies
novel human
human anti
hiv
specifically
Prior art date
Application number
TNP2009000380A
Other languages
English (en)
Inventor
Jean-Claude Chermann
Camille Haslin
Original Assignee
Urrma R & D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39473318&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000380(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Urrma R & D filed Critical Urrma R & D
Publication of TN2009000380A1 publication Critical patent/TN2009000380A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TNP2009000380A 2007-03-22 2009-09-18 Novel human anti-r7v antibodies and uses thereof TN2009000380A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89635907P 2007-03-22 2007-03-22
PCT/EP2008/053317 WO2008113833A1 (fr) 2007-03-22 2008-03-19 Nouveaux anticorps humains anti-r7v et leurs utilisations

Publications (1)

Publication Number Publication Date
TN2009000380A1 true TN2009000380A1 (en) 2010-12-31

Family

ID=39473318

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000380A TN2009000380A1 (en) 2007-03-22 2009-09-18 Novel human anti-r7v antibodies and uses thereof

Country Status (18)

Country Link
US (1) US20110123536A1 (fr)
EP (1) EP2137214A1 (fr)
JP (1) JP2010521189A (fr)
KR (1) KR20100014495A (fr)
CN (1) CN101679515A (fr)
AR (1) AR066396A1 (fr)
AU (1) AU2008228246A1 (fr)
BR (1) BRPI0808287A2 (fr)
CA (1) CA2681130A1 (fr)
CL (1) CL2008000820A1 (fr)
IL (1) IL201034A0 (fr)
MA (1) MA31256B1 (fr)
MX (1) MX2009009982A (fr)
RU (1) RU2009138922A (fr)
TN (1) TN2009000380A1 (fr)
TW (1) TW200846363A (fr)
WO (1) WO2008113833A1 (fr)
ZA (1) ZA200906516B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108117586A (zh) 2010-08-10 2018-06-05 洛桑聚合联合学院 红细胞结合性治疗剂
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
KR102039751B1 (ko) 2011-05-31 2019-11-01 바이오젠 엠에이 인코포레이티드 Pml의 위험을 판단하는 방법
WO2014193804A1 (fr) 2013-05-28 2014-12-04 Biogen Idec Ma Inc. Méthodes d'évaluation de risque de développement d'une lemp
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
CA2946064C (fr) 2014-02-21 2023-09-26 Ecole Polytechnique Federale De Lausanne (Epfl) Agents therapeutiques de glycociblage
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
CN105020678B (zh) * 2015-08-04 2017-10-13 珠海金晟照明科技有限公司 透镜单元、透镜组件和路灯灯头
WO2017196819A2 (fr) * 2016-05-09 2017-11-16 Icahn School Of Medicine At Mount Sinai Anticorps anti-cytomégalovirus humain (hcmv) largement neutralisant et leurs procédé d'utilisation
WO2018232176A1 (fr) 2017-06-16 2018-12-20 The University Of Chicago Compositions et procédés d'induction d'une tolérance immunitaire
EP3774890A4 (fr) * 2018-03-26 2022-05-04 The University of Chicago Procédés et compositions permettant de cibler une lectine de type c de cellules endothéliales sinusoïdales du foie et des ganglions lymphatiques (lsectine)
EP3790577A4 (fr) 2018-05-09 2022-04-27 The University of Chicago Compositions et procédés d'induction d'une tolérance immunitaire
US20230374114A1 (en) * 2020-04-16 2023-11-23 Dana-Farber Cancer Institute, Inc. Coronavirus antibodies and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735984B1 (fr) * 1995-06-30 1997-09-19 Inst Nat Sante Rech Med Vaccin contre des agents infectieux ayant une phase intracellulaire, composition pour le traitement et la prevention des infections a hiv, anticorps et procede de diagnostic
US20030021800A1 (en) * 1995-06-30 2003-01-30 Jean-Claude Chermann Vaccine against infectious agents having an intracellular phase, composition for the treatment and prevention of HIV infections, antibodies and method of diagnosis
FR2836146B1 (fr) * 2002-02-15 2005-01-07 Urrma R & D IMMUNOGLOBULINE IgG3 MARQUEUR DE PROTECTION CONTRE LES MALADIES VIRALES INFECTIEUSES ET SES UTILISATIONS

Also Published As

Publication number Publication date
MA31256B1 (fr) 2010-03-01
ZA200906516B (en) 2010-05-26
CL2008000820A1 (es) 2008-08-22
BRPI0808287A2 (pt) 2014-10-07
AR066396A1 (es) 2009-08-19
RU2009138922A (ru) 2011-04-27
AU2008228246A1 (en) 2008-09-25
CN101679515A (zh) 2010-03-24
EP2137214A1 (fr) 2009-12-30
MX2009009982A (es) 2010-03-04
TW200846363A (en) 2008-12-01
KR20100014495A (ko) 2010-02-10
US20110123536A1 (en) 2011-05-26
IL201034A0 (en) 2010-05-17
CA2681130A1 (fr) 2008-09-25
WO2008113833A1 (fr) 2008-09-25
JP2010521189A (ja) 2010-06-24

Similar Documents

Publication Publication Date Title
TN2009000380A1 (en) Novel human anti-r7v antibodies and uses thereof
CA2821268C (fr) Anticorps monoclonal humain ayant une specificite pour la proteine e du virus de la dengue de serotype 1 et utilisations de celui-ci
MX2010004482A (es) Anticuerpos anti-proteina g vsr.
MX2009011500A (es) Anticuerpos anti-mdl-1.
MX2012011543A (es) Tratamiento de sarcoidosis empleando celulas madre placentarias.
MX2012001882A (es) Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
WO2009126688A3 (fr) Compositions et procédés nouveaux pour le traitement de maladies de nature immunitaire
PH12015501558B1 (en) Human antibodies to respiratory syncytial virus f protein and methods of use thereof
NZ590343A (en) Compositions monovalent for cd28 binding and methods of use
WO2006015035A8 (fr) Composés utiles pour l'infection par hpv
UA109633C2 (uk) Антитіло людини проти тканинного фактора
MX2011011670A (es) Inmunoglobulinas de dominio variable dual y usos de las mismas.
PT2126049E (pt) Anticorpos contra citomegalovírus humano (hcmv)
MX2020012426A (es) Anticuerpos anti-cd38.
TN2009000285A1 (en) Human cytomegalovirus neutralising antibodies and use thereof
MX350200B (es) Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74.
MX2010005642A (es) Preparados, metodos y estuches para el tratamiento de la tos.
MY160445A (en) Dual Variable Domain Immunoglobulins And Uses Thereof
WO2011035205A3 (fr) Anticorps dirigés contre candida, leurs collectes et procédés d'utilisation
WO2013013025A3 (fr) Anticorps anti-cxcr4 et leurs procédés d'utilisation
MY187325A (en) Anti-5t4 antibodies and antibody-drug conjugates
WO2009114560A3 (fr) Compositions et procédés pour le diagnostic et le traitement d’une infection à cytomégalovirus
NZ594347A (en) Antibodies against human tweak and uses thereof
WO2010135521A3 (fr) Compositions et procédés pour le traitement et le diagnostic de la grippe
EP2538970A4 (fr) Traitement ou prévention d'une infection